BIIB Q4 2020 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q4 2020 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.9B-22.3% YoY

Gross Profit

$2.4B82.8% margin

Operating Income

-$331M-11.6% margin

Net Income

$358M12.5% margin

EPS (Diluted)

$2.32

QoQ Revenue Growth

-15.5%

Cash Flow

Operating Cash Flow

-$367M

Free Cash Flow

-$468M

Stock-Based Comp.

$49M

Balance Sheet

Total Assets

$24.6B

Total Liabilities

$13.9B

Stockholders' Equity

$10.7B

Cash & Equivalents

$1.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.9B	$3.7B	-22.3%
Gross Profit	$2.4B	$3.2B	-26.7%
Operating Income	-$331M	$1.8B	-118.6%
Net Income	$358M	$1.4B	-75.1%

Revenue Segments

Product

$2.3B81%

Revenues from anti-cd20 therapeutic programs

$419M15%

Product and Service, Other

$132M5%

Geographic Segments

Non-US

$1.2B52%

UNITED STATES

$1.1B48%